Schizophrenia is a severely impacting serious mental illness that presents numerous difficulties to those who suffer from it, their families, and society. While much effort has been invested in understanding successful treatments, it is still a major issue in public health. This review assesses the advances and issues in the management of schizophrenia in the 21st century, paying special attention to drugs, psychosocial techniques, and connected specialty care. Medications for antipsychotics and psychosocial procedures have shown potential to relieve symptoms and improve functioning, while Recovery-Oriented Care and Psychological Trauma Recovery focus on early diagnosis, combined treatment, and sustained attention. However, many questions remain that need to be answered, including access to care, unmet needs, and discrepancies. Today’s neuroscience research, along with genetic studies and novel therapy options, such as long-acting injectable antipsychotics or telepsychiatry, offers the possibility of further progress being made. Future research exploring fields such as neuroscience, genetics, and implementation science could lead to increasingly effective strategies for people with schizophrenia.
References
[1]
Elvevag, B. and Goldberg, T.E. (2000) Cognitive Impairment in Schizophrenia Is the Core of the Disorder. Critical Reviews in Neurobiology, 14, 1-21. https://doi.org/10.1615/critrevneurobiol.v14.i1.10
[2]
Bradshaw, T., Lovell, K., Bee, P. and Mairs, H. (2005) Why Do Adults with Schizophrenia Have Poorer Physical Health than the Rest of the Population? Mental Health Practice, 9, 28-30. https://doi.org/10.7748/mhp2005.12.9.4.28.c1897
[3]
Read, J.H. (2013) Prejudice, Stigma and “Schizophrenia”: The Role of Bio-Genetic Ideology. In: Models of Madness: Psychological, Social and Biological Approaches to Psychosis, Routledge, 157-177.
[4]
Janoutová, J.J. (2016) Epidemiology and Risk Factors of Schizophrenia. Neuroendocrinology Letters, 37, 1-8.
[5]
Medalia, A. and Choi, J. (2009) Cognitive Remediation in Schizophrenia. Neuropsychology Review, 19, 353-364. https://doi.org/10.1007/s11065-009-9097-y
[6]
Such, P., Olivares, J.M., Arias, L., Troels Berg, M. and Madera, J. (2021) Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate. Neuropsychiatric Disease and Treatment, 17, 1881-1892. https://doi.org/10.2147/ndt.s303292
[7]
Kasckow, J., Felmet, K., Appelt, C., Thompson, R., Rotondi, A. and Haas, G. (2014) Telepsychiatry in the Assessment and Treatment of Schizophrenia. Clinical Schizophrenia & Related Psychoses, 8, 21-27. https://doi.org/10.3371/csrp.kafe.021513
[8]
Montoya, N., Hawkins, B., Townsend, J. and Lewis, S. (2020) Use of Evidence-Based Practices in Recreational Therapy for Schizophrenia Spectrum Disorder Recovery: A Descriptive Study of Current Practices. Therapeutic Recreation Journal, 54, 128-149. https://doi.org/10.18666/trj-2020-v54-i2-9962
[9]
Lally, J. and MacCabe, J.H. (2015) Antipsychotic Medication in Schizophrenia: A Review. British Medical Bulletin, 114, 169-179. https://doi.org/10.1093/bmb/ldv017
[10]
Stroup, T.S. and Gray, N. (2018) Management of Common Adverse Effects of Antipsychotic Medications. World Psychiatry, 17, 341-356. https://doi.org/10.1002/wps.20567
[11]
Klein, M.O., Battagello, D.S., Cardoso, A.R., Hauser, D.N., Bittencourt, J.C. and Correa, R.G. (2018) Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cellular and Molecular Neurobiology, 39, 31-59. https://doi.org/10.1007/s10571-018-0632-3
[12]
Sikich, L., Frazier, J.A., McClellan, J., Findling, R.L., Vitiello, B., Ritz, L., et al. (2008) Double-blind Comparison of First-and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-Affective Disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. American Journal of Psychiatry, 165, 1420-1431. https://doi.org/10.1176/appi.ajp.2008.08050756
[13]
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., et al. (2013) Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. The Lancet, 382, 951-962. https://doi.org/10.1016/s0140-6736(13)60733-3
[14]
Mitchell, A.J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W. and de Hert, M. (2011) Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 39, 306-318. https://doi.org/10.1093/schbul/sbr148
[15]
Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C., et al. (1999) Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. American Journal of Psychiatry, 156, 1686-1696. https://doi.org/10.1176/ajp.156.11.1686
[16]
Samara, M.T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., et al. (2016) Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia. JAMA Psychiatry, 73, 199-210. https://doi.org/10.1001/jamapsychiatry.2015.2955
[17]
Porcelli, S., Balzarro, B. and Serretti, A. (2012) Clozapine Resistance: Augmentation Strategies. European Neuropsychopharmacology, 22, 165-182. https://doi.org/10.1016/j.euroneuro.2011.08.005
[18]
Kontaxakis, V.P., Ferentinos, P.P., Havaki-Kontaxaki, B.J., Paplos, K.G., Pappa, D.A. and Christodoulou, G.N. (2006) Risperidone Augmentation of Clozapine. European Archives of Psychiatry and Clinical Neuroscience, 256, 350-355. https://doi.org/10.1007/s00406-006-0643-9
[19]
Nucifora, F.C., Woznica, E., Lee, B.J., Cascella, N. and Sawa, A. (2019) Treatment Resistant Schizophrenia: Clinical, Biological, and Therapeutic Perspectives. Neurobiology of Disease, 131, Article ID: 104257. https://doi.org/10.1016/j.nbd.2018.08.016
[20]
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P.M., Patel, M.X. and Korhonen, P. (2011) A Nationwide Cohort Study of Oral and Depot Antipsychotics after First Hospitalization for Schizophrenia. American Journal of Psychiatry, 168, 603-609. https://doi.org/10.1176/appi.ajp.2011.10081224
[21]
Keks, N.A., Ingham, M., Khan, A. and Karcher, K. (2007) Long-Acting Injectable Risperidone Olanzapine Tablets for Schizophrenia or Schizoaffective Disorder. British Journal of Psychiatry, 191, 131-139. https://doi.org/10.1192/bjp.bp.105.017020
[22]
Kim, H.O., Seo, G.H. and Lee, B.C. (2020) Real-World Effectiveness of Long-Acting Injections for Reducing Recurrent Hospitalizations in Patients with Schizophrenia. Annals of General Psychiatry, 19, Article No. 1. https://doi.org/10.1186/s12991-019-0254-2
[23]
Brissos, S., Veguilla, M.R., Taylor, D. and Balanzá-Martinez, V. (2014) The Role of Long-Acting Injectable Antipsychotics in Schizophrenia: A Critical Appraisal. Therapeutic Advances in Psychopharmacology, 4, 198-219. https://doi.org/10.1177/2045125314540297
[24]
Chaudhari, B., Saldanha, D., Kadiani, A. and Shahani, R. (2017) Evaluation of Treatment Adherence in Outpatients with Schizophrenia. Industrial Psychiatry Journal, 26, 215-222. https://doi.org/10.4103/ipj.ipj_24_17
[25]
Edelman, E.M. (2010) Patients’ Perception of Family Involvement and Its Relationship to Medication Adherence for Persons with Schizophrenia and Schizoaffective Disorders. https://rucore.libraries.rutgers.edu/rutgers-lib/27445/
[26]
Haddad, C., Salameh, P., Sacre, H., Clément, J. and Calvet, B. (2023) Effects of Antipsychotic and Anticholinergic Medications on Cognition in Chronic Patients with Schizophrenia. BMC Psychiatry, 23, Article No. 61. https://doi.org/10.1186/s12888-023-04552-y
[27]
Solmi, M., Croatto, G., Piva, G., Rosson, S., Fusar-Poli, P., Rubio, J.M., et al. (2022) Efficacy and Acceptability of Psychosocial Interventions in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-Analytic Evidence. Molecular Psychiatry, 28, 354-368. https://doi.org/10.1038/s41380-022-01727-z
[28]
Ventriglio, A., Ricci, F., Magnifico, G., Chumakov, E., Torales, J., Watson, C., et al. (2020) Psychosocial Interventions in Schizophrenia: Focus on Guidelines. International Journal of Social Psychiatry, 66, 735-747. https://doi.org/10.1177/0020764020934827
[29]
Agrawal, A., Kaur, R.D. and Sidana, A. (2022) Cognitive Behavioral Therapy-Based Approach for Management of Persistent Hallucinations in Treatment-Resistant Schizophrenia. Industrial Psychiatry Journal, 31, 376-377. https://doi.org/10.4103/ipj.ipj_137_21
[30]
Mueser, K.T., Deavers, F., Penn, D.L. and Cassisi, J.E. (2013) Psychosocial Treatments for Schizophrenia. Annual Review of Clinical Psychology, 9, 465-497. https://doi.org/10.1146/annurev-clinpsy-050212-185620
[31]
Pilling, S., Bebbington, P., Kuipers, E., Garety, P., Geddes, J., Orbach, G., et al. (2002) Psychological Treatments in Schizophrenia: I. Meta-Analysis of Family Intervention and Cognitive Behaviour Therapy. Psychological Medicine, 32, 763-782. https://doi.org/10.1017/s0033291702005895
[32]
Lenior, M.E., Dingemans, P.M.A.J., Linszen, D.H., De Haan, L. and Schene, A.H. (2001) Social Functioning and the Course of Early-Onset Schizophrenia. British Journal of Psychiatry, 179, 53-58. https://doi.org/10.1192/bjp.179.1.53
[33]
Li, Z. and Arthur, D. (2005) Family Education for People with Schizophrenia in Beijing, China. British Journal of Psychiatry, 187, 339-345. https://doi.org/10.1192/bjp.187.4.339
[34]
Lehman, A.F. and Steinwachs, D.M. (2003) Evidence-Based Psychosocial Treatment Practices in Schizophrenia: Lessons from the Patient Outcomes Research Team (PORT) Project. The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 31, 141-154. https://doi.org/10.1521/jaap.31.1.141.21939
[35]
Dickerson, F.B. and Lehman, A.F. (2006) Evidence-Based Psychotherapy for Schizophrenia. Journal of Nervous & Mental Disease, 194, 3-9. https://doi.org/10.1097/01.nmd.0000195316.86036.8a
[36]
Bellack, A.S. (2004) Skills Training for People with Severe Mental Illness. Psychiatric Rehabilitation Journal, 27, 375-391. https://doi.org/10.2975/27.2004.375.391
[37]
Kemp, R., Hayward, P., Applewhaite, G., Everitt, B. and David, A. (1996) Compliance Therapy in Psychotic Patients: Randomised Controlled Trial. British Medical Journal, 312, 345-349. https://doi.org/10.1136/bmj.312.7027.345
[38]
Zimmermann, G., Favrod, J., Trieu, V.H. and Pomini, V. (2005) The Effect of Cognitive Behavioral Treatment on the Positive Symptoms of Schizophrenia Spectrum Disorders: A Meta-Analysis. Schizophrenia Research, 77, 1-9. https://doi.org/10.1016/j.schres.2005.02.018
[39]
Bengtsson-Tops, A. and Hansson, L. (1999) Subjective Quality of Life in Schizophrenic Patients Living in the Community. Relationship to Clinical and Social Characteristics. European Psychiatry, 14, 256-263. https://doi.org/10.1016/s0924-9338(99)00173-x
[40]
Repper, J. and Watson, E. (2012) A Year of Peer Support in Nottingham: Lessons Learned. The Journal of Mental Health Training, Education and Practice, 7, 70-78. https://doi.org/10.1108/17556221211236466
[41]
Holmedal Byrne, K. and Gustafsson, B.M. (2024) Implementation Study of “Building Resilience,” Including Positive Psychology Interventions and Positive Emotion Regulation Training in Patients with Severe Mental Illness in an Adult Outpatient Psychiatric Mental Health Setting: An Exploratory Clinical Trial. Behavior Modification, 48, 537-560. https://doi.org/10.1177/01454455241269842
[42]
Lenroot, R., Bustillo, J.R., Lauriello, J. and Keith, S.J. (2003) Integration of Care: Integrated Treatment of Schizophrenia. Psychiatric Services, 54, 1499-1507. https://doi.org/10.1176/appi.ps.54.11.1499
[43]
May, P.R. (1968) Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. Science House.
[44]
Hogarty, G.E. (1974) Drug and Sociotherapy in the Aftercare of Schizophrenic Patients. Archives of General Psychiatry, 31, 609-618. https://doi.org/10.1001/archpsyc.1974.01760170011002
[45]
Mueser, K.T., Sengupta, A., Schooler, N.R., Bellack, A.S., Xie, H., Glick, I.D., et al. (2001) Family Treatment and Medication Dosage Reduction in Schizophrenia: Effects on Patient Social Functioning, Family Attitudes, and Burden. Journal of Consulting and Clinical Psychology, 69, 3-12. https://doi.org/10.1037/0022-006x.69.1.3
[46]
Falloon, I.R.H., Held, T., Roncone, R., Coverdale, J.H. and Laidlaw, T.M. (1998) Optimal Treatment Strategies to Enhance Recovery from Schizophrenia. Australian & New Zealand Journal of Psychiatry, 32, 43-49. https://doi.org/10.3109/00048679809062704
[47]
Lin, C. and Lane, H. (2019) Early Identification and Intervention of Schizophrenia: Insight from Hypotheses of Glutamate Dysfunction and Oxidative Stress. Frontiers in Psychiatry, 10, Article 93. https://doi.org/10.3389/fpsyt.2019.00093
[48]
American Psychiatric Association (2006) American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006.
[49]
Busch, A.B., Lehman, A.F., Goldman, H. and Frank, R.G. (2009) Changes over Time and Disparities in Schizophrenia Treatment Quality. Medical Care, 47, 199-207. https://doi.org/10.1097/mlr.0b013e31818475b7
[50]
West, J.C., Wilk, J.E., Olfson, M., Rae, D.S., Marcus, S., Narrow, W.E., et al. (2005) Patterns and Quality of Treatment for Patients with Schizophrenia in Routine Psychiatric Practice. Psychiatric Services, 56, 283-291. https://doi.org/10.1176/appi.ps.56.3.283
[51]
Kreyenbuhl, J., Nossel, I.R. and Dixon, L.B. (2009) Disengagement from Mental Health Treatment among Individuals with Schizophrenia and Strategies for Facilitating Connections to Care: A Review of the Literature. Schizophrenia Bulletin, 35, 696-703. https://doi.org/10.1093/schbul/sbp046
[52]
Emsley, R., Chiliza, B., Asmal, L. and Lehloenya, K. (2011) The Concepts of Remission and Recovery in Schizophrenia. Current Opinion in Psychiatry, 24, 114-121. https://doi.org/10.1097/yco.0b013e3283436ea3
[53]
Bellack, A.S. (2005) Scientific and Consumer Models of Recovery in Schizophrenia: Concordance, Contrasts, and Implications. Schizophrenia Bulletin, 32, 432-442. https://doi.org/10.1093/schbul/sbj044
[54]
Jahangir, M., Zhou, J., Lang, B. and Wang, X. (2021) Gabaergic System Dysfunction and Challenges in Schizophrenia Research. Frontiers in Cell and Developmental Biology, 9, Article 663854. https://doi.org/10.3389/fcell.2021.663854
[55]
Cui, L., Xu, X. and Cao, F. (2021) Building the Precision Medicine for Mental Disorders via Radiomics/Machine Learning and Neuroimaging. Frontiers in Neuroscience, 15, Article 685005. https://doi.org/10.3389/fnins.2021.685005
[56]
Vita, A., Minelli, A., Barlati, S., Deste, G., Giacopuzzi, E., Valsecchi, P., et al. (2019) Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. Frontiers in Pharmacology, 10, Article 402. https://doi.org/10.3389/fphar.2019.00402
[57]
Maheu, M.M., Pulier, M.L., McMenamin, J.P. and Posen, L. (2012) Future of Telepsychology, Telehealth, and Various Technologies in Psychological Research and Practice. Professional Psychology: Research and Practice, 43, 613-621. https://doi.org/10.1037/a0029458
[58]
Alegría, M., Alvarez, K., Ishikawa, R.Z., DiMarzio, K. and McPeck, S. (2016) Removing Obstacles to Eliminating Racial and Ethnic Disparities in Behavioral Health Care. Health Affairs, 35, 991-999. https://doi.org/10.1377/hlthaff.2016.0029
[59]
Satcher, D. (2000) Mental Health: A Report of the Surgeon General—Executive Summary. Professional Psychology: Research and Practice, 31, 5-13. https://doi.org/10.1037/0735-7028.31.1.5
